The VIVUS, Inc. (NASDAQ:VVUS) announced that management will present an overview of the company at the 13th Annual Needham Healthcare Conference on April 8, 2014, 3:40pm EDT at The Westin Grand Central Hotel, New York.VIVUS, Inc. (NASDAQ:VVUS) shares after opening at $5.81 moved to $5.83 on last trade day and at the end of the day closed at $5.42. Company price to sales ratio in past twelve months was calculated as 6.90 and price to cash ratio as 1.63. VIVUS, Inc. (NASDAQ:VVUS) showed a negative weekly performance of -5.24%.
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) announced the closing of its initial public offering of 3,263,010 ordinary shares at a public offering price of $13.50 per share, which included 425,610 ordinary shares issued upon the exercise in full of the underwriters’ option to purchase additional ordinary shares to cover over-allotments. The aggregate gross proceeds from the sale of the shares were approximately $44.1 million, before deducting underwriting discounts, commissions and other estimated offering expenses. The net proceeds from the sale of the shares, after deducting underwriting discounts, commissions and other estimated offering expenses were approximately $39.7 million. The ordinary shares issued in the offering are listed on the NASDAQ Capital Market under the trading symbol “GLMD. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) shares fell -4.19% in last trading session and ended the day on $10.75.
Array Biopharma Inc (NASDAQ:ARRY) announced that its Chief Executive Officer, Ron Squarer, will present at the RBC Capital Markets Global Healthcare and Cowen Annual Healthcare Conferences. The public is welcome to participate in the conferences through webcasts on the Array BioPharma website. Array Biopharma Inc (NASDAQ:ARRY) shares moved down -5.01% in last trading session and was closed at $4.17, while trading in range of $4.09-$4.52. Array Biopharma Inc (NASDAQ:ARRY) year to date performance is -16.77%.
Onconova Therapeutics Inc (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for its year ended December 31, 2013. 2013 was an important year for Onconova. During the year we completed our initial public offering and fully enrolled the Phase 3 ONTIME trial in higher risk myelodysplastic syndromes (MDS) for our lead product candidate, rigosertib. Onconova Therapeutics Inc (NASDAQ:ONTX) weekly performance is -9.68%. On last trading day company shares ended up $5.69. Onconova Therapeutics Inc (NASDAQ:ONTX) distance from 50-day simple moving average is -43.12%. Analysts mean target price for the company is $11.50.
Leave a Reply